APA

Ammassari A., Stöhr W., Antinori A., Molina J., Schwimmer C., Domingo P., Thalme A., Di Pietro M., Wallet C., Pozniak A., Richert L. & Raffi F. (20191003). Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. : Journal of acquired immune deficiency syndromes (1999).

Chicago

Ammassari Adriana, Stöhr Wolfgang, Antinori Andrea, Molina Jean-Michel, Schwimmer Christine, Domingo Pere, Thalme Anders, Di Pietro Massimo, Wallet Cedrick, Pozniak Anton, Richert Laura and Raffi François. 20191003. Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. : Journal of acquired immune deficiency syndromes (1999).

Harvard

Ammassari A., Stöhr W., Antinori A., Molina J., Schwimmer C., Domingo P., Thalme A., Di Pietro M., Wallet C., Pozniak A., Richert L. and Raffi F. (20191003). Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. : Journal of acquired immune deficiency syndromes (1999).

MLA

Ammassari Adriana, Stöhr Wolfgang, Antinori Andrea, Molina Jean-Michel, Schwimmer Christine, Domingo Pere, Thalme Anders, Di Pietro Massimo, Wallet Cedrick, Pozniak Anton, Richert Laura and Raffi François. Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. : Journal of acquired immune deficiency syndromes (1999). 20191003.